Corporate Overview

Pharmacokinetics, neurotoxicity, and preclinical efficacy

  1. Sustained intracranial exposure profiles

  2. Excellent translational pharmacokinetic and biodistribution characteristics

  3. Favorable neurotoxicity observations

  4. Near complete eradication with prolonged survival in malignant glioma models

Scientific Validation

  1. Oral presentation on the pharmacokinetics, biodistribution, and neurotoxicity of lead drug candidate (2026 SNO)

  2. Poster presentation on the preclinical efficacy of OncoPDCs (2025 SNO)

  3. Peer-reviewed publication in Neuro-Oncology Advances (2025)

Platform Differentiation

  1. Multi-week intracranial and local drug retention

  2. Sustained tumor exposure following a single administration

  3. Minimal systemic exposure following local delivery

  4. Reduced risk of systemic toxicity

  5. Compatibility with highly potent payloads

Pipelines and Regulatory Momentum

  1. Five U.S. FDA Orphan Drug Designations (ODDs) across malignant glioma and pancreatic cancer programs

  2. Three FDA INTERACT meetings to align with FDA regulatory expectations and development guidances

  3. IND-enabling studies for planned first-in-human clinical programs in malignant glioma and pancreatic cancer

  4. Regulatory achievements were accomplished primarily through the company’s internal scientific and regulatory capabilities without reliance on external regulatory consulting firms, reflecting a highly capital-efficient development strategy

  5. Selected for the BTR-NTA Program to receive clinical development guidance for brain tumor therapeutics

Clinical Readiness

  1. Excellamol is currently conducting GLP toxicokinetics and safety pharmacology to support IND submissions and first-in-human clinical trials in 2028.

  2. For CMC development and GMP manufacturing, the company has established collaborations with Sterling Pharma Solutions and KBI Biopharma

  3. Clinical development collaborations include: Asan Medical Center for pancreatic cancer clinical studies and UCSF Helen Diller Family Comprehensive Cancer Center as a candidate site for first-in-human malignant glioma clinical trials

Intellectual Property

  1. Excellamol is securing a robust global intellectual property estate around the Self-Depot OncoPDC™ platform and its therapeutic applications, with granted and pending patent filings across major international jurisdictions.

Value Drivers

  1. Regulatory validation via multiple FDA ODDs

  2. Precision oncology platform enables sustained tumor exposure

  3. Differentiation in rare and high-unmet-need oncology indications

  4. Broad applicability across multiple therapeutic payloads

  5. FDA-aligned clinical development strategy